BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Giermaziak Wojciech (Home Medical Library, Poland)
Tytuł
The Influence of the Reimbursement Act on the Polish Pharmaceutical Market
Źródło
Journal of Health Policy and Outcomes Research, 2013, nr 1, s. 72-81, rys., tab., bibliogr. 4 poz.
Słowa kluczowe
System ochrony zdrowia, Leki, Refundacja leków, Rynek farmaceutyczny
Health care system, Drugs, Reimbursement of medicines, Pharmaceutical market
Uwagi
summ.
Abstrakt
On 12th May 2011, the Act on Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Purposes and Medical Devices was introduced to the Polish healthcare system. After one year of the Act being operational, the government concluded that the bill was bringing certain benefits to the taxpayer by, sometimes, drastic cuts in the immediate profits of producers, importers and retail and wholesale businesses, both in private and public healthcare. Simultaneously with government actions, various analyses are underway from the private sector initiative (including, among other, IMS Health Poland, Pharma Expert, Kamsoft, WHO, and some European law firms). The implemented changes in the pricing process of medicinal and medical products (a flexible system of price setting); an array of medications with identical/near identical profile into, so-called, limit groups and narrowing the scope of reimbursement to drugs, administered in compliance with their intended use, as well as the integration of the new legal provisions with the already existing regulations have brought substantial financial benefits to the taxpayer. Rationalisation of expenses, incurred by NFZ (the Healthcare Fund), was the primary goal of the Reimbursement Act, while extending the scope for the use of medication particles, as well as of the latest medical technologies, e.g., in new or modified medication programmes. The aim of this study was an analysis of the overall functioning and results of the Reimbursement Act after one year from its implementation.(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. IMS Health Polska -current comments and develop the Reimbursement Act, the specific source is placed in the text at a specific citation
  2. PharmaExpert - current comments and develop the Reimbursement Act, the specific source is placed in the text at a specific citation
  3. WHO Poland - data of Conference of European Review of Social Determinants of Health and Health Inequalities in Europe, Johannes Siegrist
  4. Polish Pharmaceutical Chamber (Naczelna Izba Aptekarska)
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2013.3.7
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu